Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 40Colonic Neoplasms 9Rectal Neoplasms 8Neoplasms 4Neoplasm Metastasis 4Stomach Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Metastatic Gastric Adenocarcinoma 1HER2 IHC3+ Advanced Colorectal Cancer 1Gastric and Gastroesophageal Junction Adenocarcinoma 1Gastric Cancer Adenocarcinoma Metastatic 1Gastric Adenocarcinoma 1Gallbladder Neoplasms 1Clinical Stage III Gastric Cancer AJCC v8 1Bile Duct Neoplasms 1Advanced Gastric Cancer 1

Interventions

Gastrectomy 4apatinib 3Taxes 3S 1 (combination) 3Oxaliplatin 3Cisplatin 3sintilimab 2Paclitaxel 2Hyperthermic Intraperitoneal Chemotherapy 2Drug Therapy 2Docetaxel 2Albumin-Bound Paclitaxel 2trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1tipiracil 1taxane 1pembrolizumab 1durvalumab 1disitamab vedotin 1cabozantinib 1andecaliximab 1XELOX 1Trifluridine 1Tegafur 1Tadalafil 1SHR-1701 1Resistance Training 1Radiotherapy 1Platinum 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastric Adenocarcinoma × Trifluridine × Gastrointestinal × Clear all
NCT04074343 2024-02-02

TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma

University of California, Irvine

Phase 1 Completed
20 enrolled 9 charts
Gastrointestinal

Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡